Brinzolamide

證據等級: L5

預測適應症: 10 個

Brinzolamide: From Open-Angle Glaucoma to Primary Hereditary Glaucoma

One-Sentence Summary

Brinzolamide (AZOPT®) is a topical carbonic anhydrase II inhibitor widely used to reduce elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension. The TxGNN model predicts it may be effective for Primary Hereditary Glaucoma with a prediction score of 99.48%, however no clinical trials and no publications specifically targeting this genetic subtype have been identified — the biological rationale relies entirely on mechanistic extrapolation from the extensive open-angle glaucoma evidence base.

Quick Overview

Item	Content
Original Indication	Open-angle glaucoma / Ocular hypertension
Predicted New Indication	Primary Hereditary Glaucoma
TxGNN Prediction Score	99.48%
Evidence Level	L4 (Mechanistic inference; no hereditary glaucoma-specific trials or literature)
Taiwan Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Research Question

Why is This Prediction Reasonable?

Brinzolamide is a highly selective inhibitor of carbonic anhydrase II (CA II), the enzyme that catalyzes CO₂ hydration to bicarbonate in the ciliary body epithelium. By blocking this step, brinzolamide disrupts active ion transport into the posterior chamber, reducing aqueous humor production and thereby lowering IOP by up to 18% from baseline. This mechanism is independent of the aqueous outflow pathway — meaning it works regardless of what is causing the drainage obstruction.

Primary hereditary glaucoma encompasses a spectrum of genetically defined subtypes, including juvenile open-angle glaucoma (MYOC mutations), adult-onset hereditary glaucoma (OPTN mutations), and congenital glaucoma (CYP1B1 mutations causing trabecular meshwork and Schlemm’s canal developmental defects). Despite their diverse genetic origins, all these subtypes converge on the same downstream pathology: elevated IOP from impaired trabecular meshwork function and increased aqueous outflow resistance. Since brinzolamide reduces aqueous production rather than improving outflow, it addresses the IOP endpoint irrespective of the genetic aetiology — making the mechanistic extrapolation from sporadic OAG to hereditary glaucoma biologically sound.

The TxGNN knowledge graph prediction (99.48%) reflects this pharmacological overlap. The extensive Phase 3 RCT evidence base in primary open-angle glaucoma (48+ registered trials, total enrollment exceeding 3,600 patients across completed studies) provides a strong indirect foundation. The key unanswered question is whether patients with congenital trabecular malformations show equivalent IOP-lowering response to CA inhibition compared to sporadic OAG populations — and whether paediatric systemic absorption risk for brinzolamide has been adequately characterised for neonatal and infant subpopulations.

Clinical Trial Evidence

Currently no related clinical trials registered specifically for primary hereditary glaucoma.

Context note: Extensive Phase 3 RCT evidence exists for open-angle glaucoma (TxGNN ranks 2–4: “glaucoma 1, open angle”, “glaucoma”, “open angle glaucoma”), including multiple completed large-scale trials. The 10 most relevant trials for the broader glaucoma evidence base are summarised below for reference:

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01309204	Phase 3	Completed	1,184	Largest OAG trial: Brinzolamide/Brimonidine fixed-dose combination non-inferior to concomitant use in IOP lowering
NCT01297920	Phase 3	Completed	1,062	Brinzolamide 1%/Brimonidine 0.2% fixed combination vs. individual components TID in OAG; 3-month + 3-month safety extension
NCT01297517	Phase 3	Completed	1,001	Fixed combination Brinzolamide/Brimonidine vs. monotherapy TID in OAG: efficacy and safety confirmed
NCT05022004	Phase 3	Completed	599	Therapeutic equivalence of generic Brinzolamide 1% vs. Azopt® in primary OAG and ocular hypertension
NCT02512042	Phase 3	Completed	973	Bioequivalence study of generic Brinzolamide vs. Azopt® in chronic OAG
NCT02339584	Phase 3	Completed	493	Fixed combination Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL BID vs. unfixed combination: IOP-lowering comparison
NCT00314171	Phase 3	Completed	437	Core OAG/ocular hypertension safety and efficacy study
NCT04944290	Phase 3	Completed	447	Generic Brinzolamide/Brimonidine 1% vs. Simbrinza® in primary OAG
NCT01978600	Phase 4	Completed	89	24-hour IOP control quality with Simbrinza™ — clinically relevant for day-round pressure management
NCT00758342	Phase 4	Terminated	37	Brinzolamide 1% as adjunctive therapy in chronic angle-closure glaucoma — only direct trial in non-OAG subtype; terminated early, limited data

Literature Evidence

Currently no related literature available specifically for primary hereditary glaucoma.

Context note: The broader open-angle glaucoma evidence base includes 20+ publications. The most relevant are:

PMID	Year	Type	Journal	Key Findings
26526633	2016	Systematic Review	Ophthalmology	Network meta-analysis of first-line medications for POAG; brinzolamide ranked among effective agents
39677168	2024	RCT (Head-to-head)	Cureus	Brinzolamide/Timolol vs. Dorzolamide/Timolol in Indian POAG patients; Phase 3; confirms efficacy across ethnic populations
38598266	2024	Comparative Study	J Ocul Pharmacol Ther	Brinzolamide-Brimonidine vs. Latanoprost-Timolol in POAG/OHT; 1-year prospective data
31293419	2019	Systematic Review & Meta-analysis	Front Pharmacol	Brinzolamide as add-on to prostaglandin analogues or β-blockers; efficacy and safety confirmed across pooled studies
25064721	2014	RCT	Ophthalmology	Twice-daily Brinzolamide/Brimonidine fixed combination vs. monotherapy in OAG/OHT — Phase 3 pivotal trial
26648686	2015	Clinical Effectiveness	Clin Ophthalmol	Brinzolamide 1%/Brimonidine 0.2% fixed combination for POAG; adherence benefits of fixed-dose approach
14565787	2003	Narrative Review	Drugs & Aging	Foundational review of brinzolamide as primary therapy in POAG and ocular hypertension; establishes 18% IOP reduction benchmark
18312166	2008	Drug Review	Expert Opin Pharmacother	Brinzolamide mechanism, retinal blood flow improvement, and long-term OAG management
35026861	2022	RCT	J Clin Pharm Ther	Direct evidence in acute primary angle-closure: Brinzolamide effective in sequential treatment of acute angle closure (131 eyes) — supports use beyond OAG
39870471	2025	Case Report	BMJ Case Reports	⚠️ Safety signal: Brinzolamide-induced ciliary body effusion causing secondary angle closure and myopic shift — important monitoring consideration

Taiwan Market Information

Brinzolamide is not currently approved or marketed in Taiwan. No regulatory authorizations are on record, and no approved indication text is available from this source.

Global context for reference: Brinzolamide is internationally available as:

AZOPT® 1% (monotherapy, approved in USA, EU, and multiple markets for POAG/OHT)

Simbrinza® (Brinzolamide 1% / Brimonidine 0.2%, approved in USA and EU)

Azarga® (Brinzolamide 1% / Timolol 0.5%, approved in EU and other markets)

This global approval profile is evidenced by the multinational clinical trial programme documented in ranks 2–4 of this report.

Safety Considerations

Formal safety data (package insert warnings, contraindications) from Taiwan regulatory sources are not available for this candidate. No drug-drug interactions were identified in the database query.

The following safety signals are identified from clinical literature:

Drug-induced secondary angle closure (2025 case report): PMID 39870471 describes brinzolamide-induced unilateral ciliary body effusion presenting as acute angle closure with myopic shift, resolving after drug cessation and atropine. This is a clinically important consideration if brinzolamide is used in hereditary glaucoma patients with anatomically shallow anterior chambers or pre-existing angle-closure risk — particularly relevant for CYP1B1-associated congenital glaucoma.
Sulfonamide class effects: As a sulfonamide derivative, brinzolamide carries a class-level risk for hypersensitivity reactions in sulfonamide-sensitive patients.
Paediatric systemic absorption: For congenital glaucoma subtypes requiring treatment in neonates and infants, systemic absorption of topical brinzolamide is of concern; punctal occlusion and lid closure technique are recommended.

Please refer to the current SmPC for complete safety information.

Conclusion and Next Steps

Decision: Research Question

Rationale: Primary hereditary glaucoma shares the core pathophysiology of elevated IOP with sporadic open-angle glaucoma — the mechanistic basis for brinzolamide use is sound — but no clinical data exist specifically in genetically-defined hereditary glaucoma populations, making this purely an inference from the extensive OAG evidence base. The prediction score of 99.48% reflects knowledge graph proximity, not validated clinical efficacy in this subtype.

To proceed, the following is needed:

Retrospective registry analysis or chart review in genetically-confirmed hereditary glaucoma patients (MYOC, OPTN, CYP1B1 mutation carriers) treated with CA inhibitors to characterise IOP response
Paediatric pharmacokinetic data for brinzolamide in congenital glaucoma populations (neonatal/infant systemic exposure quantification)
MOA documentation from DrugBank (currently unavailable) to formally establish CA II selectivity profile for regulatory submissions
Taiwan TFDA package insert retrieval for local contraindication and warning data
Evaluation of whether hereditary glaucoma subtype (developmental malformation vs. MYOC-linked adult-onset) affects CA inhibitor IOP-response magnitude
If evidence is supportive: design a prospective sub-study within existing hereditary glaucoma registries (e.g., international GIGA consortium) to formally characterise brinzolamide response as adjunctive therapy
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.